Relapsing Multiple News Today

ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May ...

Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.

Janelle Annalee Cruz, Staff Sergeant (Retired) 41 of Whittaker Road, Carthage, passed away after a yearlong courageous battle with cancer on Saturday, November 12, 2022, at Samaritan Medical Center in

Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.

NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I &

Ponesimod provides clinical benefit over teriflunomide for fatigue among patients with relapsing multiple sclerosis regardless of disease activity status.

Nach Fingolimod, Siponimod und Ozanimod ist nun der vierte Sphingosin-1-Phosphat-Rezeptor-Modulator auf dem Markt. Ponesimod ist zugelassen bei Patienten m...

Press release content from Business Wire. The AP news staff was not involved in its creation. New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio April 8, 2021 GMT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 8, 2021-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Ac...

Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021 News provided by Share this article Share this article TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27. Nine Janssen-sponsored data abstracts on MS research will...